Predictors of mortality among TB-HIV Co-infected patients being treated for tuberculosis in Northwest Ethiopia: a retrospective cohort study by unknown
RESEARCH ARTICLE Open Access
Predictors of mortality among TB-HIV Co-infected
patients being treated for tuberculosis in
Northwest Ethiopia: a retrospective cohort study
Balewgizie Sileshi1*, Negussie Deyessa2, Belaineh Girma3, Muluken Melese3 and Pedro Suarez4
Abstract
Background: Tuberculosis (TB) is the leading cause of mortality in high HIV-prevalence populations. HIV is driving
the TB epidemic in many countries, especially those in sub-Saharan Africa. The aim of this study was to assess
predictors of mortality among TB-HIV co-infected patients being treated for TB in Northwest Ethiopia.
Methods: An institution-based retrospective cohort study was conducted between April, 2009 and January, 2012.
Based on TB, antiretroviral therapy (ART), and pre-ART registration records, TB-HIV co-infected patients were
categorized into “On ART” and “Non-ART” cohorts. A Chi-square test and a T-test were used to compare categorical
and continuous variables between the two groups, respectively. A Kaplan-Meier test was used to estimate the
probability of death after TB diagnosis. A log-rank test was used to compare overall mortality between the two
groups. A Cox proportional hazard model was used to determine factors associated with death after TB diagnosis.
Results: A total of 422 TB-HIV co-infected patients (i.e., 272 On ART and 150 Non-ART patients) were included for a
median of 197 days. The inter-quartile range (IQR) for On ART patients was 140 to 221 days and the IQR for
Non-ART patients was 65.5 to 209.5 days. In the Non-ART cohort, more TB-HIV co-infected patients died during TB
treatment: 44 (29.3%) Non-ART patients died, as compared to 49 (18%) On ART patients died. Independent
predictors of mortality during TB treatment included: receiving ART (Adjusted Hazard Ratio (AHR) =0.35 [0.19-0.64]);
not having initiated cotrimoxazole prophylactic therapy (CPT) (AHR = 3.03 [1.58-5.79]); being ambulatory
(AHR = 2.10 [1.22-3.62]); CD4 counts category being 0-75cells/micro liter, 75-150 cells/micro liter, or 150-250 cells/micro
liter (AHR = 4.83 [1.98-11.77], 3.57 [1.48-8.61], and 3.07 [1.33-7.07], respectively); and treatment in a hospital
(AHR = 2.64 [1.51-4.62]).
Conclusions: Despite the availability of free ART from health institutions in Northwest Ethiopia, mortality was high
among TB-HIV co-infected patients, and strongly associated with the absence of ART during TB treatment. In
addition cotrimoxazol prophylactic therapy remained important factor in reduction of mortality during TB
treatment. The study also noted importance of early ART even at higher CD4 counts.
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Background
The human immunodeficiency virus (HIV) pandemic
presents a massive challenge to the control of tubercu-
losis (TB) at all levels. The synergy between TB and HIV
is strong; in high HIV prevalence population, TB is a
leading cause of morbidity and mortality, and HIV is
driving the TB epidemic in many countries, especially
those in sub-Saharan Africa [1]. TB is often the first clin-
ical indication that a person has an underlying HIV in-
fection and, as a result, TB services can be a critical
entry point for HIV prevention, care, and treatment [2].
The syndemic interaction between HIV and TB epi-
demics has had deadly consequences around the world,
and disproportionately affects people in Africa [3].
In patients with advanced acquired immune deficiency
syndrome (AIDS) and active TB, highly active antiretro-
viral therapy (HAART) may be administered concur-
rently with the TB treatment to prevent opportunistic
infections which may superimpose and accelerate HIV
disease progression [4]. The World Health Organization
(WHO) currently recommends that ART should be initi-
ated for all TB-HIV co-infected patients irrespective of
their CD4 counts [5].
Despite international recommendations and the proven
benefit of ART, physicians remain reluctant to prescribe
ART to HIV-infected TB patients, due to concerns about
overlapping toxicity, drug-drug interactions, pill burden, and
immune reconstitution inflammatory syndrome (IRIS) [6].
Understanding the predictors of mortality for TB-HIV
co-infected patients in the local context is critical for
Ethiopia to improve TB-HIV co-infected patients’ co-
management. To date, there is inadequate data on pre-
dictors of mortality among TB-HIV co-infected patients
in Ethiopia. To address this, the USAID-funded Help
Ethiopia Address Low TB (HEAL TB) project conducted
a retrospective study in Northwest Ethiopia to determine
predictors of mortality among TB-HIV co-infected pa-
tients. The study also aimed to compare the survival rate
between TB-HIV co-infected patients who received ART
and did not receive ART. It is anticipated that findings
from this study will contribute to the body of knowledge
that informs TB-HIV program planers, decision makers,
and project implementers by providing predictors of




We conducted a retrospective cohort study in govern-
mental health institutions in Bahir Dar, Northwest
Ethiopia, from August, 2011 to January, 2012. Bahir Dar
is located in Northwest Ethiopia, 565 kilometers from
Addis Ababa. In these health institutions, patients diag-
nosed as having HIV in any of HIV counseling and
testing protocols (i.e., Voluntary counseling and testing,
Provider initiated HIV counseling and testing units) are
registered in Pre-ART and ART log books according to
the status of disease progression. Patients are also re-
ferred to ART clinics for pre-ART and ART follow up
from private health facilities within Bahir Dar and health
facilities outside of Bahir Dar. Felege Hiwot Referral
Hospital and Bahir Dar Health Center have provided
pre-ART and ART services since 2005 and other health
centers in the town began providing these services in
2009. Felege Hiwot Referral Hospital’s 2011 annual re-
port showed that the facility had detected 1,600 TB
cases, enrolled 13,590 people living with HIV/AIDS
(PLWHA) in ART clinic, and started 9,222 PLWHA
on ART. As of 2011 annual report, there were 5,547
PLWHA taking ART at Felege Hiwot Referral Hospital.
According to 2011/12 report of Bahir Dar Health Center,
a total of 4, 420 PLWHA ever enrolled of which 1, 133
were currently on ART. In the same year the health cen-
ter reported 135 TB patients. The 2011/12 report of
Abay Health Center showed 756 PLWHA enrolled of
which 326 were currently on ART. The health center
also reported 162 TB patients. Han Health Center
reported 1, 726 PLWHA were ever enrolled (407 cur-
rently on ART) and 112 TB patients were registered in
the year 2011/12.
Participants
All TB-HIV co-infected patients who started ART before
initiating TB treatment, and those who started ART
while being treated for TB, were included in the “On
ART” cohort. Patients who did not receive ART until
completion of TB treatment were included in the “Non-
ART” cohort. For both cohorts, inclusion criteria in-
cluded TB-HIV co-infected patients, aged 15 years or
older, who were diagnosed with TB at any time during
pre-ART and or ART follow-up since April 2009, and
who completed TB treatment before January 2012. Pa-
tients who had been diagnosed for both TB and HIV
during their initial visit to the health facility were also
included for the study.
Enrollment procedures for study subjects
Bahir Dar town was chosen purposely to get adequate
number of sample with proper and complete patient
record profile. In the town there are seven governmen-
tal health institutions, of which three were newly
opened during data collection period. Therefore we in-
cluded four health institutions (Felege Hiwot Refferal
Hospital, Bahir Dar Health Center, Han Health Center
and Abay Health Center) for the study which delivers
TB service, Pre-ART and ART service for TB/HIV co-
infected patients. During April 2009 – September 2011,
849 TB-HIV co-infected patients were registered in four
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health institutions. A total of 422 TB-HIV co-infected
patients (272 ‘On ART’ and 150 ‘Non-ART’ cohorts)
were included for the study [Figure 1].
Data collection
Nurses who work in TB and ART clinics were selected
to collect data from August, 2011 to January, 2012.
Data was collected retrospectively by reviewing the files
of TB-HIV co-infected patients in Bahir Dar. All pro-
files of TB-HIV co-infected patients between April 2009
and January 2012 were considered for data collection.
Pre-ART registers, lab requests, follow-up forms, anti-
TB record forms, ART intake forms, and patient cards
were reviewed. The patients’ date of death was
extracted from TB registration log books. Data quality
was assured by using a pre-tested data collection tool
and trained data collectors. Two public health profe-
ssionals (Master of public health) had provided con-
tinuous supervision and monitoring. Supervisors, data
clerks and investigators had checked completeness and
consistency of data before and after data entry.
Measurement of variables
Death from any cause during TB treatment was listed
as “on-treatment TB death,” according to the WHO’s
TB treatment outcomes definitions [7]. If the date of
ART was more than one week before TB treatment ini-
tiation, that person was classified as “on ART prior to
TB treatment”. Patients who initiated ART at any time
before TB treatment was completed were classified as
“having received ART during TB treatment”.
Patients were diagnosed with smear positive pulmon-
ary tuberculosis (PTB+), if one of the sputum examina-
tions was positive for acid fast bacilli (AFB). Patients
were diagnosed with extra pulmonary tuberculosis (EPTB)
if physicians suspected or observed that the TB infection
had spread outside of the respiratory organs [5].
Functional status is measured at base line, and a per-
son is categorized into working “able to perform usual
work in or out of the house”; Ambulatory “able to per-
form activities of daily living” and Bedridden “not able
to perform activities of daily living”.
Statistical analysis
Data was entered to EpiData 3.1a for Windows. Statis-
tical package for social science (SPSS) version 16.0 for
Windows and Stata version 11.0 were used for analysis.
Data was cleaned and edited by simple frequencies and
cross tabulation before analysis. The response variable
was survival time, defined as “time in days transpired
from the date of initial TB treatment to death” or, in
the case of individuals who did not die (censored), “the
time in days transpired to complete TB treatment”.
Mean (with standard deviation), median (with inter
quartile range [IQR]), and frequencies (as percentages)
were used to describe patients’ characteristics in each
cohort. A Chi-square test and a T-test were used to
compare categorical and continuous variables between
the two cohorts, respectively. The Kaplan-Meier test
was used to estimate the probability of death and the
median time to death after TB diagnosis. The log-rank
test was used to compare time to death between the
two groups. The Cox proportional hazard model was
used to determine predictors of death after TB diagno-
sis. All statistically significant (p < 0.05) factors in the
bivariate analysis were included in the final model. The
crude and adjusted hazard ratio (HR) and its 95% confi-
dence interval (CI) were estimated.
Ethical issues
Ethical clearance for this study was obtained from the Re-
view Ethics Committee of the School of Public Health at
Addis Ababa University. To preserve patient confidential-
ity, nurses working in the ART clinics extracted the data
from patients’ medical records. Moreover, no personal
identifiers were used on the data collection form.
Results
A total of 422 TB-HIV co-infected patients (272 On
ART patients and 150 Non-ART patients) were included
for the study and followed for a median of 197 days with
an IQR of 140 to 221 days among On ART patients and
191 days among Non-ART patients with an IQR of 65.5
to 209.5 days.
Baseline socio-demographic characteristics of the study
subjects
In this study, the two cohorts were not statistically differ-
ent in any of the identified socio-demographic attributes.
Adult TB patients registered from April 2009 to
September 2011 (n= 2,773)
TB-HIV co-infected patients (n=849)





Out come not registered 
(n=46)
HIV status known after
TB treatment initiation 
(n=64)
Enrolled in the 
study (n=422)
Not enrolled (n=66)
ART status not 
determined (n=37)
Patient card not 
found (n=29)
Figure 1 Enrollment of TB-HIV co-infected patients in the
study, 2012.
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The median age of study subjects in both cohorts was
30 years with an IQR of 27 to 37.5 years in the On ART
cohort and 25 to 38 years in the Non-ART cohort. There
were more female than male subjects in both cohorts, with
141 (53.4%) women in the On ART cohort and 83 (56.5%)
women in the Non-ART cohort. More than one third of
patients in both cohorts had completed secondary school
with 93 (34.8%) in the On ART cohort and 50 (35.7%) in
the Non-ART cohort (see Table 1).
Clinical characteristics of the study subjects
The clinical condition of study subjects within the two
cohorts was not statistically different among any of the
identified variables, except for history of prophylactic
medication. In the On ART cohort, a higher proportion
(51.6%) of patients had used prophylactic medication, as
compared to patients in the Non-ART cohort (27.1%),
(X2 = 21.721; df (1); p = 0.000). Among all study subjects,
more than one third had had at least one past opportun-
istic infection. In the On ART cohort, 58 (22.4%) study
subjects had a history of past TB treatment, as compared
to just 31 (21.7%) in the Non-ART cohorts. Data showed
that the On ART and Non-ART cohorts had statistically
different median CD4 counts (T = 10.305; p = 0.000): the
On ART cohort had a much lower CD4 count with, a
median of 114 cells/micro liter (μl) and an IQR of 58 to
185 cells/μl, as compared to the Non-ART cohort,
which had a median of 291 cells/μl and an IQR of 183.5
to 448 cells/μl (see Table 2).
There was a statistically significant difference in the
type of TB diagnosis between the cohorts. In the On
ART group, 107 (39.3%) study subjects had smear nega-
tive PTB, whereas only 36 (24.0%) had smear negative
PTB in the Non-ART group (X2 =10.434; df = 2; p =
0.005). A higher proportion (93.3%) of study subjects in
the On ART cohort had received CPT, as compared to
those in the Non-ART cohort (77%) (see Table 2).
Comparison of mortality between the on ART and Non-
ART cohorts
The 422 study subjects contributed a cumulative total of
2,274.4 person month observations (PMO) to this study;
the On ART cohort contributed 1,545.03 PMO and the
Non-ART cohort contributed 729.37 PMO. In the Non-
ARTcohort, 44 (29.3%) of TB-HIV co-infected patients died
during TB treatment, which represented a higher percent-
age than the 49 patients (18%) who died in the On ART co-
hort. The incidence rate of mortality in the Non-ART
cohort was 6.03 per 100 person months observations
(PMO), (95% CI: 4.5, 8.1) and the mortality incidence in the
Table 1 Baseline socio-demographic characteristics of TB-HIV co- infected patients in Bahir Dar town, 2012
Base line variable On ART (n = 272) Non-ART (n = 150) X2 Value (df) P-Value
Residency (n = 407)
Urban 235 (90.7%) 129 (87.2%) 1.271 0.260
Rural 24 (9.3%) 19 (12.8%) (1)
Age (n = 408)
Mean ± SD 32.58 ± 9.123 31.98 ± 9.837 0.753♦ 0.452
Median (IQR) 30 yrs (27-37.5) 30 yrs (25-38)
Sex (n = 411)
Male 123 (46.6%) 64 (43.5%) 0.355 0.551
Female 141 (53.4%) 83 (56.5%) (1)
Religion (n = 411)
Orthodox 226 (85.3%) 117 (80.2%) 5.962 0.183
Muslim 26 (9.8%) 18 (12.3%) (2)
Others 13 (4.9%) 11 (7.5%)
Marital status (n = 415)
Single 76 (28.1%) 55 (37.9%) 7.901 0.131
Married 108 (40.0%) 57 (39.3%) (3)
Divorced 52 (19.2%) 24 (16.6%)
Widowed 34 (12.6%) 9 (6.2%)
Educational status (n = 407)
Not educated 77 (28.8%) 40 (28.6%) 0.765 0.858
Primary 61 (22.8%) 35 (25.0%) (3)
Secondary 93 (34.8%) 50 (35.7%)
Tertiary 36 (13.5%) 15 (10.7%)
♦ = T-test Statistic for independent sample test used.
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On-ART cohort was 3.2 per 100 PMO (95% CI: 2.40, 4.20).
The overall incidence rate of mortality during TB treatment
was 4.09 per 100 PMO (95% CI: 3.34, 5.01). Results from
the On ART cohort showed that incidence of mortality in
the first month of TB treatment was 5.4 per 100 PMO and,
in the second month of TB treatment, was 4.8 per 100
PMO. The corresponding values in Non-ART cohort was
16.9 per 100 PMO and 5.9 per 100 PMO in the first and
second months of TB treatment, respectively. The median
time to death was 59 days in the On ART cohort and
29.5 days in the Non-ARTcohort. The overall probability of
survival in the On ART cohort was significantly greater
than in the Non-ART cohort (log rank statistic = 8.93,
df = 1, P = 0.003); (see Figure 2).
Predictors of mortality in TB-HIV Co-infected patients
during TB treatment
The bivariate analysis showed that the risk of death de-
creased by 46% (HR = 0.54, 95% CI: 0.36-0.82) in the On-
ART cohort. Compared to smear negative PTB patients,
smear positive PTB patients had a 2.02 (95% CI: 1.07-3.83)
times higher risk of death and EPTB patients had a 2.77
(95% CI: 1.61-4.75) times higher risk of death. In addition,
patients who did not start CPT had a 3.15 times higher
risk of mortality (95% CI: 1.95-5.11). Compared to the ref-
erence group, TB patients 45 years old or more (HR =
2.58, 95% CI: 1.34-4.92), patients with ambulatory and
bedridden functional status (HR = 2.76, 95% CI: 1.71-4.47
and HR = 3.88, 95% CI: 2.15-7.02 respectively), and pa-
tients with CD4 count less than 75 cells/μl (HR = 2.08,
95% CI: 1.17- 3.70) had an increased risk of mortality
during TB treatment. In the study, completing primary
school -reduced risk of death by 55% (HR = 0.45, 95% CI:
0.22-0.90), compared to not educated TB-HIV co-infected
patients (see Table 3).
ART status, CPT status, CD4 count, functional status,
type of TB diagnosis, and type of health institution were
independent predictors of mortality after controlling for
Table 2 Baseline clinical characteristics of TB-HIV co- infected patients in Bahir Dar town, 2012
Base line variable On ART (n = 272) Non-ART (n = 150) X2 Value (df) P- Value
Past OIs (n = 366)
Yes 105 (43.6%) 55 (44.0%) 0.006 0.937
No 136 (56.4%) 70 (56.0%) (1)
Past TB Treatment (n = 402)
Yes 58 (22.4%) 31 (21.7%) 0.027 0.869
No 201 (77.6%) 112 (78.3%) (1)
Functional status (n = 397)
Working 159 (60.9%) 80 (58.8%) 1.363 0.506
Ambulatory 72 (27.6%) 44 (32.4%) (2)
Bedridden 30 (11.5%) 12 (8.8%)
CD4 count (n = 408)
Mean ± SD 132.9 ± 94.42 312.78 ± 192.8 10.30♦ 0.000*
Median (IQR) 114 (58-185) 291 (183.5-448)
Hgb level (mmHg)(n = 357)
Mean ± SD 11.36 ± 2.3 11.46 ± 1.83 0.063♦ 0.95
Median (IQR) 11.3 (10.0-13.0) 12.0 (10.12-13.0)
TB diagnosis
Smear Positive PTB 53 (19.5%) 40 (26.7%) 10.434 0.005*
Smear Negative PTB 107 (39.3%) 36 (24.0%) (2)
Extra PTB 112 (41.2%) 74 (49.3%)
CPT (n = 397)
Prescribed 239 (93.0%) 109 (77.9%) 19.19 0.000*
Not Prescribed 18 (7.0%) 31 (22.1%) (1)
Outcome of TB Treatment (n = 417)
Cure 37 (13.7%) 16 (11.0%) 8.039 0.045*
Treatment completed 167 (61.6%) 77 (52.7%) (3)
Defaulter 18 (6.6%) 9 (6.2%)
Death 49 (18.1%) 44 (30.1%)
* Significant at α = 0.05, ♦ = T-test Statistic for independent sample test used.
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the other factors. From these factors, receiving ART dur-
ing TB treatment had decreased risk of mortality by 65%
(AHR = 0.35, 95% CI: 0.19-0.64). In addition, CPT
remained an important factor in reduction of mortality
during TB treatment, in which patients without CPT
were at a 3.03 times higher risk of mortality (95% CI: 1.58,
5.79). In this study CD4 count categories 0-75 cells/μl,
75-150 cells/μl, and 150-250 cells/μl; EPTB type; being
ambulatory; and treatment in a hospital were independent
predictors of increased risk of mortality during TB treat-
ment (see Table 4).
Discussion
This study revealed the overwhelming problem of the
high mortality of TB-HIV co-infected patients during TB
treatment. More than 1 in 5 TB-HIV co-infected individ-
uals died during TB treatment. Results from this study
demonstrated that ART remained independently pro-
tective against mortality during TB treatment. In
addition not having initiated cotrimoxazole prophylactic
therapy; being ambulatory; CD4 count and treatment in
a hospital were independent predictors of mortality dur-
ing TB treatment.
In our study, the median CD4 count in the Non-ART
cohort was twice as high as the median CD4 count in the
On ART cohort. Non-ART cohorts may have been diag-
nosed as having HIV and TB, before their clinical and im-
munological conditions deteriorate. The median CD4
count among participants in this study was much higher
than the median CD4 count among participants in other
studies [8-15]. The difference may be due to the fact that
researchers in our study took CD4 counts while the study
subjects were being treated for TB or one month before
they began TB treatment and, in most cases, these study
subjects had started ART before TB diagnosis, which may
have improved their immunological status. In addition,
the results showed that 86.3% of study subjects had a CD4
count below 350 cells/μl. This is similar with a study
conducted in Zimbabwe where 84.6% of study participants
had a CD4 count below 350 cells/μl [16]. This showed that
most study subjects were in progressive immunodeficiency
condition.
There was no statistical difference in type of TB diag-
nosis between the two cohorts; 55.9% of study subjects
were diagnosed with PTB and 44.1% were diagnosed
with EPTB. This is in line with other studies [11,13,17]
but the proportion of EPTB in this study is high com-
pared to two studies conducted in India (22.9% and
31%) and one study conducted done in Thailand, which
reported that 31% of study subjects had EPTB
[10,12,18]. The variation could be a result of stage of
HIV disease, difference in TB diagnosis or epidemiology
of TB in different countries.
We found that mortality rate was high (22%) among TB-
HIV co-infected patients during TB treatment. In line with
this, previous studies have reported high mortality rates
ranging from 8.5% to 30% among TB-HIV co-infected pa-
tients prior to successful completion of TB treatment
[4,8-10,12,13,15,17-19]. In our study, death occurred in 49
of 272 patients (18%) exposed to ART during TB treatment,
compared with 44 of 150 patients (29.3%) never exposed to
ART. This finding is similar to a study conducted in India,
where death occurred in 11.3% of patients exposed to ART
during TB treatment and 24.6% of TB patients never ex-
posed to ART [10]. However, results from a study
conducted in Thailand showed 46% proportion of death
among TB-HIV co-infected patients who did not start ART
[13]. Another study in Thailand reported that 5 of 71 pa-
tients (7%) who received ART died, compared with 94 of
219 patients (43%) who did not receive ART (RR 0.2; 95%
Figure 2 Kaplan-Meier estimate of survival among TB-HIV co-infected patients in Bahir Dar town, 2012.
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CI: 0.1–0.4) [18]. In Malawi, a total of 132 of 660 patients
(20%) died during an eight-month course of anti-TBs treat-
ment, which is consistent with our finding of 22% [20].
In this study, we have documented that the risk of
mortality was high among subjects in the first month of
TB treatment. This may be due to delayed presentation
Table 3 Predictors of mortality among TB-HIV co-infected patients in Bahir Dar town, 2012
Variable Number at risk Number of death Incidence of mortality per 100
person month observation (95% CI)
Crude hazard ratio (95% CI)
ART
Started 272 49 3.17 (2.39, 4.19) 0.54 (0.36, 0.82)*
Not started 150 44 6.03 (4.49, 8.11) 1
CPT prophylaxis
Prescribed 348 60 3.59 (2.66, 4.87) 1
Not prescribed 49 23 10.18 (6.77, 15.32) 3.15 (1.95, 5.11)*
Type of TB
Smear negative PTB 143 17 2.02 (1.26, 3.25) 1
Smear positive PTB 93 21 4.31 (2.81, 6.61) 2.02 (1.07, 3.83)*
Extra PTB 186 55 5.81 (4.46, 7.57) 2.77 (1.61, 4.78)*
Past OIs
No 206 50 4.62 (3.50, 6.09) 1
Yes 160 31 3.53 (2.48, 5.02) 0.77 (0.49, 1.20)
Past TB treatment
No 313 66 3.95 (3.10, 5.03) 1
Yes 89 18 3.58 (2.25, 5.68) 0.91 (0.54, 1.54)
Functional status
Working 239 31 2.21 (1.55, 3.14) 1
Ambulatory 116 36 6.39 (4.61, 8.87) 2.77 (1.71, 4.47)*
Bedridden 42 17 7.31 (3.81, 14.05) 3.88 (2.15, 7.02)*
CD4 count
< 75 107 33 6.22 (4.42, 8.75) 2.08 (1.17, 3.30)*
75-150 91 21 4.44 (2.90, 6.81) 1.50 (0.80, 2.82)
150-250 95 19 3.57 (2.28, 5.59) 1.24 (0.65, 2.37)
> = 250 115 18 2.89 (1.82, 4.59) 1
Health institution
Health center 226 34 2.67 (1.91, 3.72) 1
Hospital 196 59 5.89(4.57, 7.61) 2.18 (1.43, 3.33)*
Age(n = 408)
15-24 100 18 3.30 (2.08, 5.24) 1
25-34 193 40 3.79 (2.78, 5.17) 1.15 (0.66, 2.01)
35-44 69 16 4.40 (2.70, 7.18) 1.30 (0.66, 2.55)
> = 45 46 19 8.97 (5.72, 14.06) 2.58 (1.34, 4.92)*
Sex
Male 187 45 4.53 (3.36, 6.07) 1
Female 224 45 3.69 (2.75, 4.94) 0.82 (0.54, 1.24)
Educational status
Not educated 117 26 4.47 (3.05, 6.57) 1
Primary 96 11 1.93 (1.07, 3.49) 0.45 (0.22, 0.90)*
Secondary 143 37 4.82 (3.49, 6.66) 1.10 (0.66, 1.81)
Tertiary 51 13 4.48 (2.60, 7.72) 1.05 (0.54, 2.05)
*Significant at α = 0.05.
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of patients and, thus, advanced TB and HIV/AIDS, late
diagnosis of TB within health institutions, and the pres-
ence of life-threatening HIV related complications.
These results are similar to results from a study con-
ducted in Thailand which showed the first month of TB
treatment is the time of the maximum number of deaths
[21]. Another study conducted in sub-Saharan Africa
concluded that ART should be started soon after TB
diagnosis because the majority of deaths among TB-HIV
patients in this study occurred during the patients’ first
two months of TB treatment [22].
In our retrospective, institution-based study, we found
that TB-HIV co-infected patients who took ART during
TB treatment had a lower risk of death. This is consistent
with studies from several other settings [8-11,13,15,17-
19,23,24] that demonstrate the positive impact of ART on
the survival outcomes among TB-HIV co-infected pa-
tients, including successful immune restoration and reduc-
tions in morbidity and mortality.
In addition to ART, we found other immunological
factors associated with mortality. For example, mortality
rates increased in TB-HIV co-infected patients with
Table 4 Multivariate predictors of mortality among TB-HIV co-infected patients in Bahir Dar town, 2012
Variable Crude hazard ratio (95% CI) Adjusted hazard ratio (95% CI)
ART
Started 0.54 (0.36, 0.82) 0.35 (0.19, 0.64)*
Not started 1 1
CPT prophylaxis
Prescribed 1 1
Not prescribed 3.15 (1.95, 5.11) 3.03 (1.58, 5.79)*
Type of TB
Smear negative PTB 1 1
Smear positive PTB 2.02 (1.07, 3.83) 2.11 (0.95, 4.65)
Extra PTB 2.77 (1.61, 4.78) 2.39 (1.23, 4.66)*
CD4 count
< 75 2.08 (1.17, 3.30) 4.83 (1.98, 11.78)*
75-150 1.50 (0.80, 2.82) 3.57 (1.48, 8.61)*
150-250 1.24 (0.65, 2.37) 3.07 (1.33, 7.07)*
> = 250 1 1
Functional status
Working 1 1
Ambulatory 2.77 (1.71, 4.47) 2.10 (1.22, 3.62)*
Bedridden 3.88 (2.15, 7.02) 2.11 (0.98, 4.53)
Health Institution
Health center 1 1
Hospital 2.18 (1.43, 3.33) 2.64 (1.51, 4.62)*
Age(n = 408)
15-24 1 1
25-34 1.15 (0.66, 2.01) 1.17 (0.60, 2.29)
35-44 1.30 (0.66, 2.55) 0.98 (0.43, 2.23)
> = 45 2.58 (1.34, 4.92) 2.20 (0.97, 4.59)
Educational status
Not educated 1 1
Primary 0.45 (0.22, 0.90) 0.49 (0.22, 1.12)
Secondary 1.10 (0.66, 1.81) 0.88 (0.49, 1.58)
Tertiary 1.05 (0.54, 2.05) 0.65 (0.29, 1.47)
*Significant at α = 0.05. ART status, health institution type, age, educational status, functional status, CD4 count, type of TB diagnosis, and CPT initiation were
included in the model.
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lower CD4 counts. This finding is consistent with a
study in Zimbabwe, which showed that HIV-TB co-
inflected patients with a CD4 count of <50 cells/micro
litter had a 13 percent increased risk of death compared
to patients with CD4 count greater or equal to 200 cells/
micro litter [16]. Oppositely, a study conducted in
southern India showed that a CD4 count below 200/
mm3 was not associated with a higher rate of mortality
[17]. The difference between our results and these others
may be that we categorized CD4 counts into smaller in-
tervals, which better enabled us to see the effect of CD4
counts on mortality.
The risk of death during TB treatment was higher in
patients treated at a hospital compared to those treated
at a health center. The reason could be that those who
are taking care in hospitals might have advanced disease
conditions. As a result, the severely ill hospitalized pa-
tients appeared to have a greater incidence of mortality,
as compared to the less ill health center patients.
In this study TB-HIV co-infected patients with extra
PTB were at increased risk of mortality during TB treat-
ment compared to smear negative PTB patients. In other
studies PTB is associated with high risk of mortality
[10]. The possible reason may be HIV infected patients
with extra PTB were highly immune-compromised.
In our study not initiating CPT was associated with
high risk of mortality. In line with this, studies from
South India and Sub-Saharan Africa showed that not
taking CPT was significantly associated with mortality
[17,22]. In our study, however, patients who died shortly
after being diagnosed with TB and HIV may not have
had the chance to initiate CPT. This may have led us to
overestimate the benefit of CPT.
Our study was subject to several important limitations.
All TB-HIV co-infected patients who started ART before
initiating TB treatment, and those who started ART
while being treated for TB, were included in the same
group which may introduce bias. Information about
other biomedical predictors for death that may have
confounded this study, such as drug resistance, severity
of immune suppression, or co-morbidities, adherence of
medication were not available. We were also unable to
collect adequate information about specific types of
EPTB and patients’ recent CD4 counts. Since most
deaths in Ethiopia occur at home [25], it was difficult to
trace all deaths. Exclusion of patients who transferred
out of care may have also slightly confounded our
results.
Conclusions
A significant difference was observed in the mortality
rate during TB treatment between the On ART and
Non-ART cohorts. Despite the fact that ART is available
in most governmental health institutions throughout
Ethiopia, death was strongly associated with the absence
of ART during TB treatment. Risk of death was 65%
lower in TB-HIV co-infected patients treated with ART,
as compared to those not treated with ART. In addition
cotrimoxazol prophylactic therapy remained important
factor in reduction of mortality during TB treatment.
The study also noted importance of early ART even at
higher CD4 counts. To alleviate this, expanding ART
use among TB-HIV co-infected patients is critical to im-
proving the survival of these patients. Health institutions
in Ethiopia should begin treating all TB-HIV co‐infected
patients with ART, irrespective of CD4count levels, as
per the WHO recommendation.
Endnotes
a EpiData Association, Odense, Denmark.
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